DUBLIN, May 7, 2020 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that The Allergan Foundation has
fast-tracked another $2 million
dollars in charitable grants for community organizations
responding to the COVID-19 pandemic. The new grants double The
Allergan Foundation's total COVID-19 donations to date, raising the
total to $4 million. The donations
are dedicated to 57 organizations working on the front lines of the
community response to the pandemic in New
York, New Jersey,
California, Texas, Ohio,
Florida and internationally.
Included among the organizations receiving grants are the
following:
- Food Bank for New York
City
- Interfaith Food Pantry of New
Jersey
- Charitable Ventures of Orange County,
California
- Central Texas Food Bank
- Freestore Foodbank, Cincinnati,
Ohio
- Hope South Florida
- Direct Relief
"As the COVID-19 pandemic continues to adversely impact people
and communities, these essential organizations are helping the
people most in need, providing them with food, housing and mental
health services," said Brent
Saunders, Chairman of The Allergan Foundation. "We applaud
them for the critical front-line care they are providing, which The
Allergan Foundation is proud to help support."
In 2020 to date, The Allergan Foundation has awarded a total of
approximately $17 million in
charitable grants as part of its commitment to providing a lasting
and positive impact in the communities in which Allergan employees
live and work. In addition to COVID-19, the 2020 donations support
programs dedicated to Mental Health, Eye Care and Breast Health.
The 2020 grants bring The Allergan Foundation's total donations in
its 22-year history to approximately $112
million, including $61 million
since the beginning of 2015.
About The Allergan Foundation
The Allergan Foundation is a U.S.-based, private charitable
foundation committed to providing a lasting and positive impact in
the communities in which Allergan employees live and work. The
Allergan Foundation focuses its support on charitable efforts
dedicated to promoting access to quality healthcare and improving
patient diagnosis, treatment, care and quality of life. Established
in 1998, The Allergan Foundation has donated approximately
$112 million to a wide variety of
philanthropic pursuits globally. For more information, visit The
Allergan Foundation website at www.AllerganFoundation.org.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2019
and Allergan's Quarterly Report on Form 10-Q for the period ended
March 31, 2020. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7488
Media:
Lisa Brown
(862) 261 7320
View original content to download
multimedia:http://www.prnewswire.com/news-releases/the-allergan-foundation-doubles-its-covid-19-response-donations-to-4-0-million-301054787.html
SOURCE Allergan plc